Masaru Matsuda Sells 8,256 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 8,256 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $23.31, for a total transaction of $192,447.36. Following the sale, the insider directly owned 126,689 shares in the company, valued at approximately $2,953,120.59. The trade was a 6.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Masaru Matsuda also recently made the following trade(s):

• On Monday, March 2nd, Masaru Matsuda sold 8,733 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.30, for a total transaction of $220,944.90.
• On Friday, February 27th, Masaru Matsuda sold 3,325 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $27.95, for a total transaction of $92,933.75.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ ARQT traded up $0.75 during mid-day trading on Wednesday, hitting $24.17. 1,381,968 shares of the company’s stock traded hands, compared to its average volume of 1,026,236. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.17 and a quick ratio of 2.99. Arcutis Biotherapeutics, Inc. has a 1 year low of $12.42 and a 1 year high of $31.77. The company’s 50-day moving average is $23.78 and its two-hundred day moving average is $25.78. The company has a market capitalization of $3.02 billion, a P/E ratio of -172.63 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The company had revenue of $105.40 million during the quarter, compared to analysts’ expectations of $103.68 million. On average, equities analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current fiscal year.

Analyst Ratings Changes

ARQT has been the subject of several recent analyst reports. Mizuho dropped their price objective on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Guggenheim increased their target price on shares of Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, February 27th. HC Wainwright lifted their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. TD Cowen upped their price target on shares of Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, Needham & Company LLC increased their price objective on shares of Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Arcutis Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Q1 product momentum — ZORYVE net product revenue was $105.4M, up ~65% year?over?year and above consensus revenue; company said it maintained positive operating cash flow and highlighted continued branded non?steroidal share gains. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Regulatory and pipeline progress — submitted an sNDA to expand ZORYVE for infants (3–24 months), completed enrollment in the ZORYVE foam pediatric MUSE trial, and started first?in?human studies of ARQ?234. These catalysts support longer?term growth expectations. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Commercial build — expanded the dermatology sales force and is building a primary care/pediatrics organization, which could broaden ZORYVE adoption. Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analyst stance — broker consensus remains a “Moderate Buy,” supporting investor sentiment around upside to the current share price. Arcutis Receives Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: Insider sales disclosed — several executives and a director sold shares recently (executed under pre?arranged Rule 10b5?1 plans and largely to cover taxes on vested awards), which is typical after vesting and less likely to signal negative insider sentiment. Representative SEC filing: Todd Watanabe Form 4

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. lifted its position in shares of Arcutis Biotherapeutics by 325.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after purchasing an additional 833 shares during the period. Global Retirement Partners LLC purchased a new stake in Arcutis Biotherapeutics during the fourth quarter worth $35,000. EverSource Wealth Advisors LLC boosted its position in Arcutis Biotherapeutics by 124.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares in the last quarter. NewEdge Advisors LLC increased its holdings in shares of Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares during the period. Finally, Johnson Investment Counsel Inc. purchased a new position in shares of Arcutis Biotherapeutics in the 3rd quarter valued at $30,000.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.